2 days Ago By ABMN Staff
Prudential Financial Inc. decreased its position in Metagenomi, Inc. ( NASDAQ:MGX – Free Report ) by 37.
0% during the fourth quarter, Holdings Channel reports. The firm owned 13,725 shares of the company’s stock after selling 8,075 shares during the quarter. Prudential Financial Inc.
’s holdings in Metagenomi were worth $50,000 at the end of the most recent quarter. A number of other large investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its stake in shares of Metagenomi by 130.
9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after buying an additional 7,256 shares in the last quarter. Verition Fund Management LLC acquired a new position in Metagenomi in the 3rd quarter valued at about $82,000.
Geode Capital Management LLC grew its position in Metagenomi by 105.8% in the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after acquiring an additional 173,796 shares in the last quarter.
Virtu Financial LLC purchased a new stake in Metagenomi during the third quarter worth about $33,000. Finally, Marquette Asset Management LLC acquired a new stake in shares of Metagenomi during the fourth quarter worth about $184,000. Analysts Set New Price Targets A number of research analysts recently weighed in on the stock.
Wells Fargo & Company dropped their price objective on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 18th.
HC Wainwright cut their price objective on Metagenomi from $14.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd.
One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $13.00.
Metagenomi Stock Up 7.2 % Shares of NASDAQ:MGX opened at $1.48 on Friday.
Metagenomi, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $9.
67. The firm’s 50 day moving average price is $1.92 and its 200 day moving average price is $2.
34. The stock has a market cap of $55.33 million, a price-to-earnings ratio of -0.
56 and a beta of -0.27. Metagenomi ( NASDAQ:MGX – Get Free Report ) last announced its quarterly earnings data on Monday, March 17th.
The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.
01). The firm had revenue of $9.61 million during the quarter, compared to analyst estimates of $13.
18 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.
23%. During the same quarter in the previous year, the business posted ($20.05) earnings per share.
On average, equities analysts anticipate that Metagenomi, Inc. will post -2.46 EPS for the current year.
Metagenomi Company Profile ( Free Report ) Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. Recommended Stories Want to see what other hedge funds are holding MGX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Metagenomi, Inc. ( NASDAQ:MGX – Free Report ). Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.
com's FREE daily email newsletter ..
